NeoStem Announces Pricing of Common Stock; Pfizer Announces FDA Approval of DUAVEE™ Print E-mail
By Staff and Wire Reports   
Thursday, 03 October 2013 19:20
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 3, 2013.

NeoStem, Inc. (Nasdaq: NBS), a leader in the emerging cellular therapy industry, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock at a public offering price of $7.00 per share. The Company expects to receive $35,000,000 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters a 45-day option to purchase up to 750,000 additional shares of common stock. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, including AMR-001, expansion of business units, strategic transactions and other general corporate purposes.

The financing is expected to close on or about October 9, 2013, subject to the satisfaction of customary closing conditions.



========================



Pfizer Inc. (NYSE:PFE)
, a leader in the development of treatments for menopausal symptoms, is pleased to announce that the United States Food and Drug Administration (FDA) has approved DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis.

When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk and non-estrogen medication should be carefully considered. DUAVEE is a once daily tablet taken orally. It is recommended that all menopausal hormone therapies, including DUAVEE, be used for the shortest duration consistent with treatment goals and risks for the individual woman.

Pfizer anticipates that DUAVEE will be available in the U.S. in the first quarter of 2014. This is the first approval of DUAVEE in any country worldwide.



Also Thursday:



Actinium Pharmaceuticals, Inc. (OTCQB: ATNM)
, a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it will be hosting an online webinar on October 15, 2013, at 11:00 AM EDT to discuss current progress with Iomab™-B.  

The Clorox Company (NYSE: CLX)
today unveiled its updated strategic growth plan during a Clorox Analyst Day event and live webcast at its new research and development campus in Pleasanton, Calif.

Evoke Pharma, Inc. (Nasdaq:EVOK)
, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 315,000 shares of its common stock, at a price to the public of $12.00 per share.

MiMedx Group, Inc.  (NASDAQ: MDXG)
, an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that a poster detailing an EpiFix® case study received the award for the highest scoring abstract in the case study category at the recent Symposium on Advanced Wound Care ("SAWC").  

NeoStem, Inc. (Nasdaq:NBS)
, a leader in the emerging cellular therapy industry, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock at a public offering price of $7.00 per share.

NuVasive, Inc. (NASDAQ: NUVA)
, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce the domestic launch of the XLIF Decade™ Plate.

OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED)
, a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced today that it will present at the 12th Annual BIO Investor Forum to be held at The Palace Hotel, San Francisco, CA on October 9, 2013at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time).

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)
, a developer of oral drug delivery systems, announced today that it has received two additional patent approvals for its platform Protein Oral Delivery (POD™) technology in Japan and Canada.

Prosensa Holding N.V. (NASDAQ: RNA)
, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, will hold a conference call on Tuesday, October 8, 2013 at 11:00 a.m. ET / 5:00 p.m. CET to discuss recently-presented data on drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, which is exclusively licensed to GlaxoSmithKline (GSK).

Quture International, Inc. (OTCQB: QUTR)
today announced an agreement with Therapeutic Solutions International, Inc. (OTCQB: TSOI), Oceanside, CA (TSI), to implement QualOptima analytics software as a service (SaaS) for TSI, through its newly formed consulting subsidiary QualVal Solutions, LLC.

Vascular Solutions, Inc. (Nasdaq:VASC)
today announced that it will host a live webcast of its third quarter conference call on Tuesday, October 22nd at 3:30pm CST. Vascular Solutions' Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen and VP of Corporate Development, Phil Nalbone, will discuss the company's third quarter results. The company will issue an earnings news release after market close on Tuesday, October 22nd.

VG Life Sciences, Inc. (Pink Sheets: VGLS)
a publicly traded company, is a biotechnology company focused on delivering treatments for patients suffering from autoimmune and chronic inflammatory disorders.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter